This, together with the accumulating evidence that the chemokine CXCL12 pathway increases tumor resistance to both conventional therapies and biological agents [11,15,16,42] prompted us to explore whether armed oncolytic virotherapy with the CXCR4 antagonist fused in-frame with the Fc portion of murine IgG2a delivered prior to immunization would improve the vaccine’s efficacy (Figure S4). The gene discussed is CXCR4; the disease is neoplasm.